Results 1 to 10 of about 3,074 (210)

Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF [PDF]

ESC Heart Failure
Aims Few studies have focused on the effect of torsemide versus furosemide after discharge on prognosis in patients with heart failure with preserved ejection fraction (HFpEF).
Danyan Xu
exaly   +3 more sources

Comparative analysis of furosemide and torsemide efficacy in 24 hours of acute heart failure admission [PDF]

Frontiers in Pharmacology
BackgroundIntravenous (IV) furosemide and torsemide represent a cornerstone of guideline-directed medical therapy for acute heart failure (AHF). However, the evidence regarding the superiority of each agent remains controversial.MethodsThe prospective ...
Małgorzata Małek-Elikowska, Andrzej Szyszka, Julita Fedorowicz, Rafał Dankowski, Cyntia Szymańska, Artur Baszko   +5 more
doaj   +2 more sources

Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms

Pharmaceutics, 2022
Torsemide is a diuretic drug used for several cardiovascular and chronic diseases. With regard to the clinical application of torsemide, studies on individualized pharmacotherapy and modeling that take variability in pharmacokinetics (PKs) within a ...
Seung-Hyun Jeong, Hea-Young Cho, Yong-Bok Lee   +2 more
exaly   +3 more sources

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling

Pharmaceutics, 2022
Torsemide is a widely used diuretic in clinical practice. In this study, pharmacokinetic (PK) and pharmacodynamic (PD) simulations of torsemide for various population groups and exposure scenarios were performed through human-scale physiologically-based ...
Seung-Hyun Jeong, Yong-Bok Lee
exaly   +3 more sources

Real-world effectiveness and safety of torsemide and spironolactone fixed dose combination in Indian heart failure patients (RESTORE-HF study): a prospective, multicenter, observational study [PDF]

Therapeutic Advances in Cardiovascular Disease
Background: Heart failure (HF) remains a major public health challenge in India, with a need for effective and well-tolerated therapeutic strategies.
Chandrashekhar K. Ponde, Devanu Ghosh Roy, Uday Jadav, Arun Mohanty, Karan Dang, Febin Francis, Nitin Zalte, Amarnath Sugumaran, Sandesh Sawant, Senthilnathan Mohanasundaram   +9 more
doaj   +2 more sources

Structural basis for human NKCC1 inhibition by loop diuretic drugs [PDF]

The EMBO Journal
Na+–K+–Cl− cotransporters functions as an anion importers, regulating trans-epithelial chloride secretion, cell volume, and renal salt reabsorption. Loop diuretics, including furosemide, bumetanide, and torsemide, antagonize both NKCC1 and NKCC2, and are
Yongxiang Zhao, Pietro Vidossich, Biff Forbush, Junfeng Ma, Jesse Rinehart, Marco De Vivo, Erhu Cao   +6 more
doaj   +2 more sources

Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundLoop diuretics are highly natriuretic but their short duration of action permits postdiuretic sodium retention, which limits salt loss unless dietary salt is severely restricted. We tested the hypothesis that a more prolonged duration of action
Salim Shah, Bertram Pitt, D. Craig Brater, Peter U. Feig, Wen Shen, Fatima S. Khwaja, Christopher S. Wilcox   +6 more
doaj   +2 more sources

TRANSFORM-HF Trial: Choice of loop diuretic in acute heart failure does not matter! [PDF]

Journal of Family Medicine and Primary Care
The major clinical manifestations of heart failure (HF) are due to fluid retention and congestion, and thus, therapy targeting congestion plays a central role in HF management. Furosemide is by far the most commonly prescribed loop diuretic.
Akshyaya Pradhan, Arvind Jaiswal, Monika Bhandari   +2 more
doaj   +2 more sources

Effect of aliskiren, telmisartan and torsemide on cardiac dysfunction in l-nitro arginine methyl ester (l-NAME) induced hypertension in rats

Journal of Advanced Research, 2015
Comparative study of cardio protective effect of aliskiren, telmisartan, and torsemide was carried out on l-nitro arginine methyl ester (l-NAME) induced hypertension in rats. The three drugs were given daily for 8 weeks simultaneously with l-NAME, with a
Laila Ahmed Rashed, Eman
exaly   +3 more sources

Mechanistic Differences between Torsemide and Furosemide. [PDF]

J Am Soc Nephrol
Key Points Oral torsemide was not superior to furosemide in measures of renal tubular delivery or duration of action.A dose equivalence of approximately 40 mg oral furosemide:10 mg oral torsemide resulted in similar natriuresis.The two-fold higher doses of torsemide did not improve fluid status
Rao VS, Cox ZL, Ivey-Miranda JB, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang WHW, Tang WHW, Collins SP, Velazquez EJ, Mentz RJ, Wilson FP, Turner JM, Wilcox CS, Ellison DH, Fang JC, Testani JM.   +19 more
europepmc   +3 more sources